FDX1 and lung carcinoma: Similarly, integrated metabolomic–transcriptomic analyses have linked cuproptosis-associated genes (FDX1, DLAT, LIAS) with immunotherapy outcomes in cancers such as melanoma, lung cancer, and hepatocellular carcinoma.